Objectives To evaluate the efficacy and safety of patients with benign prostatic hyperplasia treated with tamsulesin and terazasin. Methods we searched PubMed, Embase, the Cachrane Library, Chinese biomedieine literature database (CBM), CNKI, VIP, reference of included studies for randomized controlled trials comparing tamsulosin with terazosin for patients with benign prostatic hyperplssia. The quality of included studies was assessed independendy by two reviewer, discrepancies were resolved by discussion with the third person. We ana-lyzed the data using Review Manager (version 4.2. 10) software. Results Twelve studies totaling 3100 patients were included. Meta analysis results are as follows: there was significant difference in IPSS [WMD =-1.24,95%Cl (-1.98,-0.51) ,dizziness [RR = 0. 38,95% CI (0.30, O. 48)] ,pestural hypotonsion [RR = 0.14,95% CI (0.03-O. 77)], thirsty [RR = O. 16,95 % CI (0.04-0. 68)] between tamsulesin group and terazesin group, there was no significant difference between the two groups in QOL [WMD = 0.04 95% CI (-O. 16, O. 24)], Qmax [WMD =-0. 18, 95%C1(-0.64, 0.28)] ,Qave [WMD=-0.39, 95% Cl(-0.84, 0.06)] ,residual urine volume [WMD =-3.46, 95% CI (-6.86,-0. 05)]. Conclusions Current clinical studies might confirm that tsmsulosin is super to terazesin for patients with benign prostatic hyperplasia in terms of improving IPSS, dizzi-ness,postural hypotension,thirsty, there was no significant difference between the two groups with regard to QOL, Qmax,Qave,residual urine volume, the results mentioned above still need to be confirmed by more large sample, high quality trials.